ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2007
The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of ¹⁸F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2011Pooled it
- Trial
- Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells.Surgery today · 2020Article
- Imaging strategies in the management of gastric cancer: current role and future potential of MRI.The British journal of radiology · 2019Review
- EGF receptor stimulation shifts breast cancer cell glucose metabolism toward glycolytic flux through PI3 kinase signaling.PloS one · 2019Article
- Article
- Predictive value of positron emission tomography for the prognosis of molecularly targeted therapy in solid tumors.OncoTargets and therapy · 2018Article
- Is Accurate N - Staging for Gastric Cancer Possible?Frontiers in surgery · 2018Article
- Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study.European radiology · 2016Article
- Observational
- Diagnosis and evaluation of gastric cancer by positron emission tomography.World journal of gastroenterology · 2014Review
- Imaging of Gastric Cancer Metabolism Using 18 F-FDG PET/CT.Journal of gastric cancer · 2014Review
- [18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer.Journal of experimental & clinical cancer research : CR · 2013Article
- Evaluation of therapeutic effect of tumor-targeted therapy.OncoTargets and therapy · 2012Article
- Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer.Journal of biomedicine & biotechnology · 2012Review
- Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies.World journal of gastroenterology · 2011Review
- Development of radiotracers for oncology--the interface with pharmacology.British journal of pharmacology · 2011Review
- Targeting the human EGFR family in esophagogastric cancer.Nature reviews. Clinical oncology · 2011Review
- Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2011Article
- High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma.Journal of cancer research and clinical oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of the study was to evaluate whether the therapy-induced reduction of the (18)F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) maximum standardized uptake value in patients with advanced gastric adenocarcinoma treated with chemotherapy plus cetuximab could predict the objective response and outcome early during the treatment.
methodsThe study was performed as a part of a phase II trial evaluating cetuximab plus the leucovorin/5-fluorouracil/irinotecan (FOLFIRI) regimen. The objective response was evaluated according to the response evaluation criteria in solid tumors (RECIST) every 6 weeks. The early metabolic response evaluated by 18F-FDG-PET was assessed according to our own evaluated cutoff value (<35%) after receiver operating characteristic (ROC) analysis.
resultsTwenty of 22 patients had positive baseline 18F-FDG-PET. The best RECIST response was: complete response (CR), 3; partial response (PR), 9; stable disease (SD), 8. Twelve patients (60%) were classified as metabolic responders and 8 (40%) as nonresponders. At the median follow-up time of 11 months, median time to disease progression (TTP) and overall survival (OS) for early metabolic responders versus nonresponders were 11 versus 5 months (P = 0.0016) and 16 versus 6 months (P = 0.1493), respectively.
conclusionThe early metabolic response evaluated by 18F-FDG-PET predicted the clinical outcome in this series of patients with advanced gastric cancer treated with chemotherapy plus cetuximab.
Indexed as
Identifiers
18095077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.